Manuscripts

Dellanna, Frank, Richard Fluck, Gerhard Lonnemann, Clarissa Wild, Andreas Iwanowitsch, Paul Audhya, Rene Meiner, and **Caty Ebel Bitoun.** "Pasco I: a 1-year long post-registration safety study on biosimilar epoetin zeta across Germany, Spain, Italy, and the United Kingdom."

Khullar, Vik, Chris C. Sexton, Christine L. Thompson, Ian Milsom, **Caty Ebel Bitoun**, and Karin S. Coyne. "The relationship between BMI and urinary incontinence subgroups: results from EpiLUTS." Neurourology and urodynamics 33, no. 4 (2014): 392-399.

Vik Khullar, Linda Cardozo, Con J. Kelleher, Timothy Hall, John Ryan,
Caty Ebel Bitoun, Amanda Darekar, Daniel Arumi and Adrian Wagg. Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder: BJU (British Journal of Urology) International Volume 112, Issue 6, pp. 820-829 –October 2013

Coyne KS, Sexton CC, Kopp ZS, **Ebel Bitoun C**, Milsom I, Chapple C. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int. 2011;Epub.

Wagg A, Khullar V, Marshall-Kehrel D, Michel MC, Oelke M, Tincello D, Darekar A, **Ebel Bitoun C**, Osterloh I, Weinstein D. Assessment of Fesoterodine Treatment in Older People With Overactive Bladder: Results of SOFIA, a Double-Blind, Placebo-Controlled Pan European Trial. Eur Urol Suppl. 2011:10(2):276-277

Wagg, Adrian, Vik Khullar, Daniela Marschall–Kehrel, Martin C. Michel, Matthias Oelke, Amanda Darekar, **Caty Ebel Bitoun**, David Weinstein, and Ian Osterloh. "Flexible–Dose Fesoterodine in Elderly Adults with Overactive Bladder: Results of the Randomized, Double–Blind, Placebo–Controlled Study of Fesoterodine in an Aging Population Trial." Journal of the American Geriatrics Society 61, no. 2 (2013): 185-193.

Khullar V, Kelleher CJ, E**bel Bitoun C**, Arumi D, Whelan L, Cardozo L. Utilization of the Self-Assessment Goal Achievement Questionnaire to Evaluate the Importance of Treatment Goals in Subjects With Overactive Bladder Symptoms. Int Urogyn J. 2010:21(1):545-546.27.

Cardozo L, Hall T, Ryan J, **Ebel Bitoun C**, Kausar I, Darekar A, Wagg Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation. A. Int Urogynecol J. 2012 Nov;23(11):1581-90. doi: 10.1007/s00192-012-1804-1. Epub 2012 May 11.

Chapple CR, Khullar V, Gabriel Z, Muston D, **Ebel Bitoun C**, Weinstein D. The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis. Eur Urol. 2008;54:543-562.

Wagg A, Khullar V, Marshall-Kehrel D, Michel MC, Oelke M, Darekar A, **Ebel Bitoun C**, Osterloh I. Efficacy and Tolerability of Fesoterodine in Older Subjects With Overactive Bladder: Results of SOFIA. J Am Geriatr Soc. 2011:9(Suppl 1):S1

Rives, J. M., M. Pannier, J. C. Castede, V. Martinot, A. Le Touze, M. C. Romana, J. Guitard, S. Bohbot, and **C. Ebel Bitoun**. "Calcium alginate versus paraffin gauze in the treatment of scalp graft donor sites." *WOUNDS-A COMPENDIUM OF CLINICAL RESEARCH AND PRACTICE* 9, no. 6 (1997): 199-205.

Le Touze, A., Robert, M., Rives, J., Guitard, J., Martinot, V., Castede, J., Pannier, M., Romana, C., Bohbot, S., **Ebel Bitoun, C.** and Magalon, G., 1997. Cicatrisation du cuir chevelu en tant que site donneur de greffe chez l'enfant: intérêt d'un alginate de calcium. *Journal des Plaies et Cicatrisations*, *7*(II), pp.137-139.

Dosage simultané de l'hémoglobine glyquée totale (HbA1C) et de la fructosamine dans 60 cas d'alterations structurales et cinétiques de l'hémoglobine
Auteur : CATY NICOLE EBEL BITOUN; Pierre-Jean Guillausseau Editeur :[S.l.] : [s.n.], 1990. Dissertation : TH.: MED.: MEDECINE: PARIS 7, LARIBOISIERE: 1990

ABSTRACTS & POSTERS

ISG 2016 : Ebel Bitoun C. « Ce-an ICT support enhance Quality of Human interaction in our day to day living? » Presented at the 10th World Conference of Gerontechnology September 28-30 2016 Nice, France

EUGMS : Ebel Bitoun C., Living at home or moving to assisted living: a personal choice or an external mandate? An observational French study of 121 residents from 5 sites P418 10th Int. Congress of the European Union Geriatric Medicine Society Abstr. no.: 507 Rotterdam September 19, 2014

SFGG : Ebel Bitoun C., La mise en place d'aides de type télésurveillance ou mobile Health (santé connectée) pourrait elle retarder l'entrée en institution? Poster N° définitif : P7.26-98.
Thème 26. Gérontechnologies 34émes Journées annuelles de la SFGG – 25-27 novembre 2014 Paris France

Congrès francophone sur la fragilité « Prévention de la fragilité : analyse du décalage entre les aspirations des patients et la réalité du terrain. » 3è congrès francophone de la Fragilité du sujet âgé Session Poster P1 Paris - 12 mars 2015

ISPOR McCarthy, G., Ebel Bitoun C., and Guy H.. "Introduction of an infliximab biosimilar (CT-P13): a five-year budget impact analysis for the treatment of rheumatoid arthritis in Ireland." *Value in Health* 16.7 (2013): A558.

EAU Schneider T, Bergqvist A, Wang JT, Wagg A, Ebel Bitoun C. Treatment with fesoterodine or tolterodine reduces symptom bother in elderly patients with overactive bladder including urgency urinary incontinence. Presented at: The 27th Annual Meeting of The European Association of Urology; February 24-28, 2012; Paris, France.

EAU Wagg A, Khullar V, Oelke M, Marschall-Kehrel D, Michel MC, Darekar A, Ebel Bitoun C, Bavendam T, Osterloh I. Effect of Treatment Response on the Decision to Escalate
EAU Antimuscarinic Dose in Elderly Subjects With Overactive Bladder. Presented at: The 27th Annual Congress of The European Association of Urology; February 24–28, 2012; Paris France.

AUA Khullar V, Sexton CC, Thompson CL, Milsom I, Ebel Bitoun C, Coyne KS. The Relationship between BMI and Urinary Incontinence Subgroups: Results from EpiLUTS. Presented at: The 107th American Urological Association Annual Meeting; May 19-23, 2012; Atlanta, GA. (poster)

AUA Khullar V, Sexton CC, Thompson CL, Milsom I, Ebel Bitoun C, Coyne KS. The Relationship between BMI and Urinary Incontinence Subgroups: Results from EpiLUTS. Presented at: The 107th American Urological Association Annual Meeting; May 19-23, 2012; Atlanta, GA. (PPT slides)

AUA Wagg A, Khullar V, Marschall-Kehrel D, Michel MC, Oelke M, Tincello DG, Darekar A, Ebel Bitoun C, Osterloh I, Weinstein D. Efficacy, Tolerability, and Patient-Reported Outcomes in Older People With Overactive Bladder Treated With Fesoterodine: Results of SOFIA, a Double-Blind, Placebo-Controlled Pan European Trial. Presented at: The 106th Annual Meeting of the American Urological Association; May 14-19, 2011; Washington, DC.

EAU Wagg A, Khullar V, Marschall-Kehrel D, Michel MC, Oelke M, Tincello DG, Darekar A, Ebel Bitoun C, Osterloh I, Weinstein D. Assessment of fesoterodine treatment in older
people with overactive bladder: Results of SOFIA, a double-blind, placebo-controlled pan European trial. Presented at: The 26th Congress of The European Association of Urology; March 18-22, 2011; Vienna, Austria.

AGS Wagg A, Khullar V, Marshall-Kehrel D, Michel MC, Oelke M, Darekar A, Ebel Bitoun C, Osterloh I. Efficacy and Tolerability of Fesoterodine in Older Subjects With Overactive
Bladder: Results of SOFIA. Presented at: the Annual Scientific Meeting of The American Geriatric Society; May 11-14, 2011; National harbor, MD.

ICS Wagg A, Khullar V, Marschall-Kehrel D, Michel MC, Oelke M, Darekar A, Ebel Bitoun C, Osterloh I, Weinstein D. Efficacy and Tolerability of Fesoterodine in Older People

With,Overactive Bladder: Results of the Open-Label Phase of the SOFIA Trial. Presented
at: The 41st Meeting of the International Continence Society; August 29–September 2,2011; Glasgow, UK. (abstract)

ICS Cardozo L, Khullar V, Hall T, Ryan J, Ebel Bitoun C, Kausar I, Darekar A, Whelan L, Wagg A. Effects of Drug Cessation in Subjects Receiving Fesoterodine for Treatment of Overactive Bladder Symptoms. Presented at: The 41st Meeting of the International Continence Society; August 29–September 2, 2011; Glasgow, UK. (abstract)

ICS & I UGA Cardozo L, Hall T, Ryan J, Ebel Bitoun C, Darekar A, Wagg A. Does Fesoterodine
Provide Efficacy, Tolerability, and Treatment Satisfaction? A Study of British Patients With the Overactive Bladder Syndrome. Presented at: The 2010 Joint Annual Meeting of ICS and IUGA; August 23–27, 2010; Toronto, ON, Canada.

ICS Cardozo L, Khullar V, Hall T, Ryan J, Ebel Bitoun C, Kausar I, Darekar A, Whelan L, Wagg A. Effects of Drug Cessation in Subjects Receiving Fesoterodine for Treatment of Overactive Bladder Symptoms. Presented at: The 41st Meeting of the International Continence Society; August 29–September 2, 2011; Glasgow, UK. (ppt slides)

Khullar V, Kelleher CJ, Ebel Bitoun C, Arumi D, Whelan L, Cardozo L. Utilization of the Self-Assessment Goal Achievement Questionnaire to Evaluate the Importance of Treatment Goals in Subjects With Overactive Bladder Symptoms. Presented at: The 2010 Joint Annual Meeting of ICS and IUGA; August 23–27, 2010; Toronto, ON, Canada

Breza J, Mišanko V, Maľa M, Zigová I, Ebel Bitoun C. Observational Study of Fesoterodine in Patients With Overactive Bladder Who Failed Previous Antimuscarinic Therapy. Presented at: The American Urological Association; May 29 - June 3, 2010; San Francisco, CA.

Castro Diaz D, Miranda P, Sanchez-Ballester F, Arumi D, Lizarraga I, Ebel Bitoun C, on behalf of the Spanish IMPACTA study group. Factors Predictive of Dissatisfaction With Overactive Bladder Treatment. Presented at: The 25th Annual Meeting of the European

Association of Urology; April 16-20, 2010; Barcelona, Spain.

Breza J, Mišanko V, Maľa M, Zigová I, Bergqvist A, Ebel Bitoun C. Observational Study of Fesoterodine in Patients With Overactive Bladder Who Failed Previous Antimuscarinic Therapy. Presented at: The 25th Annual Meeting of the European Association of Urology; April 16-20, 2010; Barcelona, Spain.

Wagg A, Khullar V, Marschall-Kehrel D, Michel MC, Oelke M, Tincello DG, Darekar A, Ebel Bitoun C, Osterloh I, Weinstein D. Patient-Reported Outcomes Show Fesoterodine is Effective in Older People for the Treatment of Overactive Bladder: Results of SOFIA, a Pan European Trial. Presented at: The 25th Annual Meeting of the European Association of Urology; April 16-20, 2010; Barcelona, Spain.

Coyne K, Sexton C, Weinstein D, Kopp Z, Chapple C, Ebel-Bitoun C, Milsom I, Kaplan S. THE IMPACT OF OAB ON MALE SEXUAL HEALTH: RESULTS FROM EPILUTS. Presented at: The 104th Annual Meeting of The American Urological Assocation; April 25-30, 2009; Chicago, Illinois.42.

Fianu-Jonasson A, Brubaker L,Kelleher C, Khullar V, Ebel Bitoun C, Weinstein D, Andersson AS, Piault-Louis E. Understanding Swedish Patients' Expectations for Treatment of Their Urinary Symptoms. Presented at: The Nordic Urogynecological Association Annual Meeting; May 14-16, 2009; Reykjavik, Iceland.

AUA Coyne K, Sexton C, Weinstein D, Kopp Z, Ebel-Bitoun C, Milsom I, Wein A, Chapple C, on behalf of the EpiLUTS Team. THE PREVALENCE OF OAB IN THE US, UK, AND SWEDEN: RESULTS FROM EPILUTS. PRESENTED AT: The 104th Annual Meeting of The American Urological Assocation; April 25-30, 2009; Chicago, Illinois.

IUGA Coyne KS, Margolis MK, Weinstein D, Ebel-Bitoun C, Khullar V. Health-Related Quality
of Life Differences Between Men and Women With OAB Treated With Fesoterodine. Presented at: The 33rd Annual Meeting of the International Urogynaecological Association; September 15–17, 2008; Taipei, Taiwan. (poster)

IUGA Chapple CR, Khullar V, Gabriel Z, Muston D, Ebel Bitoun C, Weinstein D. The Safety
and Tolerability of Antimuscarinic Treatments in Overactive Bladder: Results from an Update of a Systematic Review and Meta-analysis. Presented at: The 33rd Annual Meeting of the International Urogynaecological Association; September 15–17, 2008; Taipei, Taiwan. (poster presentation)41

IUGA Chapple CR, Khullar V, Gabriel Z, Muston D, Ebel Bitoun C, Weinstein D. The Safety and Tolerability of Antimuscarinic Treatments in Overactive Bladder: Results from an Update of a Systematic Review and Meta-analysis. Presented at: The 33rd Annual Meeting of the International Urogynaecological Association; September 15–17, 2008; Taipei, Taiwan. (oral presentation)

IUGA Chapple CR, Khullar V, Gabriel Z, Muston D, Ebel Bitoun C, Weinstein D. The Safety and Tolerability of Antimuscarinic Treatments in Overactive Bladder: Results from an Update of a Systematic Review and Meta-analysis. Presented at: The 33rd Annual Meeting of the International Urogynaecological Association; September 15–17, 2008; Taipei, Taiwan. (abstract)

IUGA Khullar V, Chapple CR, Gabriel Z, Muston D, Ebel Bitoun C, Weinstein D. The Patient-Perceived Effects of Antimuscarinic Treatment: Results From an Update of a Systematic Review and Meta-analysis. Presented at: The 33rd Annual Meeting of the International Urogynaecological Association; September 15–17, 2008; Taipei, Taiwan. (oral presentation)

IUGA Khullar V, Chapple CR, Gabriel Z, Muston D, Ebel Bitoun C, Weinstein D. The Patient-
Perceived Effects of Antimuscarinic Treatment: Results From an Update of a Systematic Review and Meta-analysis. Presented at: The 33rd Annual Meeting of the International Urogynaecological Association; September 15–17, 2008; Taipei, Taiwan. (poster)